AZD6765 + Placebo to AZD6765
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Major Depressive Disorder
Conditions
Treatment Resistant Major Depressive Disorder
Trial Timeline
Dec 1, 2009 → Dec 1, 2011
NCT ID
NCT00986479About AZD6765 + Placebo to AZD6765
AZD6765 + Placebo to AZD6765 is a phase 2 stage product being developed by AstraZeneca for Treatment Resistant Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00986479. Target conditions include Treatment Resistant Major Depressive Disorder.
What happened to similar drugs?
3 of 20 similar drugs in Treatment Resistant Major Depressive Disorder were approved
Approved (3) Terminated (3) Active (14)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986479 | Phase 2 | Completed |
Competing Products
20 competing products in Treatment Resistant Major Depressive Disorder